Form 4: Stereotaxis Director David Benfer Receives Significant Restricted Stock Unit Grant

Stereotaxis, Inc. Director David Benfer was granted 43,668 restricted share units, aligning his interests with long-term shareholder value.

Summary

• David Benfer, a Director of Stereotaxis, Inc. (STXS), acquired 43,668 shares of common stock on July 1, 2025.
• This acquisition was a grant of restricted share units (RSUs), with each unit representing one share of common stock.
• The RSUs were granted at a price of $0.
• Following this transaction, David Benfer directly owns 468,924 shares of common stock.
• He also indirectly owns 2,700 shares through his spouse and 210,255 shares through the Benfer Family Trust, D Benfer and M Benfer TTEE.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the grant itself is a neutral event as it's compensation, it aligns director interests with shareholders and is a standard practice. The potential for future dilution is a minor negative, but expected with equity compensation.

Positives

• The grant of restricted share units to Director David Benfer aligns his long-term interests with those of shareholders.
• The vesting conditions, including a five-year anniversary or change of control, incentivize sustained performance and strategic value creation.

Negatives

• The grant of restricted share units could lead to future dilution when they vest and convert into common stock.

Risks

• Potential future dilution of existing shares upon the vesting and conversion of the 43,668 restricted share units into common stock.

Future Outlook

The 43,668 restricted share units granted to Director David Benfer are set to vest on the earliest of the fifth anniversary of the award date (July 1, 2030), the termination of his service on the board, or a Change of Control as defined in the award documents.

Industry Context

This is a standard equity compensation practice for directors in publicly traded companies, aiming to align their interests with long-term shareholder value. It does not directly reflect broader industry trends beyond general corporate governance practices.

Comparison to Industry Standards

• Granting restricted share units (RSUs) to directors is a common practice across various industries, including medical technology, to incentivize long-term commitment and performance.
• The vesting period of five years or upon specific events like termination of service or change of control is typical for such long-term incentive plans, comparable to similar arrangements at companies like Intuitive Surgical (ISRG) or Medtronic (MDT) for their non-employee directors.
• The grant at a $0 price is standard for equity compensation awards, reflecting a compensation component rather than a purchase.

Corporate Governance

Related Party Transactions

• The grant of 43,668 restricted share units to David Benfer, a Director of Stereotaxis, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting of RSUs; improved alignment of director's interests with long-term shareholder value.

Next Steps

• Vesting of the 43,668 restricted share units based on the specified conditions (fifth anniversary, termination of service, or Change of Control).
• Conversion of vested restricted share units into common stock.

Key Dates

Recommendation

Keywords

Stereotaxis, STXS, Form 4, Insider Trading, Restricted Stock Units, RSU Grant, Beneficial Ownership, Director Compensation, Equity Compensation, Corporate Governance